Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.
Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
